Global U.S Biosimilars Market Outlook 2030: Industry Insights & Opportunity Evaluation, 2019-2030


U.S Biosimilars Market By Product type (Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins); By Application (Chronic & Autoimmune Disorders, Blood Disorders, Oncology, and Growth Hormone); By Manufacturer (Contract Research and Manufacturing, In-house Manufacturing); and Region –Analysis of Market Size, Share & Trends for 2016 – 2019 and Forecasts to 2029

SKU: FPG0171 Category: Tag:


U.S Biosimilars Market

Product Overview
Biosimilar drugs are extremely identical to permitted on-going biologic drugs. “Copied” or approved copies of reference biological products under patented products are biosimilars or following-on-biologics. A critical part of the overall production process is the production and evaluation of bio-referential biologics. In the conservation of feasibility and consistency between initial and biosimilar goods, the rules for biosimilars play an important role. They encompass similar medical characteristics in terms of effectiveness, security, and usefulness to initial biological products. The development and approval of biosimilars with recommended biologics is a vital feature of the overall enhancement process. Rules and regulations for biosimilars play a significant function in preserving the feasibility and stability between original biologics and biosimilars products. Several regulatory bodies like EMA and FDA keenly control the biosimilar’s profitability and enlargement.

Market Highlights
U.S Biosimilars market is estimated to reach USD XXXX Million by 2030 from USD XXXX Million in 2019. The market is anticipated to grow at a CAGR of XX% during the forecast period, i.e., 2020-2030. A growing number of patients affected by such illnesses would result in an increased incidence of chronic diseases throughout the world, in particular in developed countries, due to the increased sedentary lifestyle and the increasing practice of fast food consumption. The prevalence rate would thus raise the demand and acceptance of biosimilar drugs, stimulating business growth in the developed countries as well as in some areas. Moreover, escalating demand for Biosimilars due to low costs is likely to propel the overall market growth. According to a survey, biosimilars are projected to act as an important factor in improving the community health problem by catering to the requirements of the customer. Increasing emphasis on Research & Development activities, patent termination, current product endorsements, the cost-effectiveness of biosimilars, and reduction in healthcare costs are expected to boost the overall growth of the Biosimilars market.

Source: Fatpos Global

U.S Biosimilars Market: Segments
The U.S market has been segmented based on product type, application, and location. It has been further segmented by countries into Northern, Eastern, western and southern regions.

By Product Type (in %), US Biosimilars Market, 2019
The Recombinant non-glycosylated proteins segment is anticipated to register XX% of the volume share.
On the basis of product type, the biosimilars market is segmented into Recombinant non-glycosylated proteins and Recombinant glycosylated proteins. Recombinant non-glycosylated proteins are further segmented into human growth hormone, granulocyte colony-stimulating factor, insulin, and interferon. The Recombinant non-glycosylated proteins market held a market share of XX% in the year 2019 and is expected to grow at the fastest pace during the forecast period due to technological developments in cell technology and high-throughput logical methods are likely to facilitate efficient manufacturing of recombinant non-glycosylated proteins leading to improved sales.

By Application type (in %), US Biosimilars Market, 2019
Oncology segment accounted for XX% of the nation’s volume in 2019 and is poised to grow at the highest CAGR during the forecasted period
On the basis of application, the biosimilars market is segmented into Chronic & Autoimmune Disorders, Blood Disorders, Oncology, and Growth Hormone. Improvements in chemotherapy and cancer treatment have assisted a lot of patients to subsist, but several patients undergo negative impacts of chemotherapy leading to chemotherapy-induced anemia. Additionally, a surge in the number of people experiencing blood disorders like neutropenia, anemia, and others will enhance the sales of biosimilars. The recent sanction of biosimilars for cancer treatment and the fat number of oncology products in the channel is a major driving factor.

By Manufacturer type (in %), US Biosimilars Market, 2019
In-house manufacturing segment to boost the growth
On the basis of the manufacturer, the biosimilars market is segmented into In-house Manufacturing, and Contract Research & Manufacturing. The In-house manufacturing segment of the biosimilar market assists the businesses to check and measure each phase of the manufacturing and trims down other costs involved. Moreover, the elasticity and competence of the work offered by in-house manufacturing help the functional and monetary abilities of the company.

The region segment can be further divided into four major types including Eastern US, Northern US, Western US, and the Southern US.

Source: Fatpos Global

U.S Biosimilars Market: Drivers and Restraints
Cost-Effectiveness to increase the demand for the market
With the lifestyle becoming more sedentary and a growing number of people affected by chronic diseases, there needs to be an emphasis on reducing healthcare costs. Biosimilars are likely to play a crucial role as they are cost-effective and will save a huge amount of money becoming easily affordable for the general public. Moreover, an increase in Research & development activities, patent expiration of biologics, and other factors are likely to drive the overall growth of the market.

Huge costs involved are expected to hinder the market demand
In the less-developed and emerging nations, enormous costs associated with the production of biosimilar drugs would likely hinder progress. In the lack of strict legislation, consumer commitment to a brand, doctors’ inability to prescribe biosimilars, and others, the growth of the biosimilars market is further hindered by the lack of customers’ loyalty.

U.S Biosimilars Market: Region
U.S to hold the largest market share during the forecast period
U.S accounted for the major share of XX% during 2019 and is estimated to dominate the biosimilars market. The American market is to be propelled due to the prevalence of key research & development centers. Moreover, US is the most developed and economically stable nation, and major players belonging to the state are supposed to boost the overall growth in the development of biosimilars. Asia-Pacific is anticipated to register a healthy growth rate during the forecast period due to the increasing geriatric population, ill-eating habits of the millennial, rising consumption of tobacco and alcohol. These factors are to fuel the overall market growth.

The region segment can be further divided into four major types including Eastern US, Northern US, Western US, and the Southern US.

Source: Fatpos Global

The US Biosimilars Market is further segmented by region into:

Eastern US Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR

Northern US Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR

Western US Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR

Southern US Market Size, Share, Trends, Opportunities, Y-o-Y Growth, CAGR

US Biosimilars Market: Competitive landscape
Biosimilar key players leverage advantages in orphan biosimilars. As inexpensive care choices for patients in need of biologics, biosimilars are growing rapidly. As new treatments are highly prevalent, corporations have a heightened aim to direct progress in biosimilars. Having expanded the availability of low-cost biology, companies are making growing efforts to meet unfulfilled patient needs of rare diseases. For instance, the strategic alliance for marketing CT-P10 and CT-P6 in the US & Canada was founded by Teva drug companies Ltd. and Celltrion Healthcare in October 2016.

US Biosimilars Market: Impact of COVID-19
There are many experimental regimens worldwide to try to find suitable for Covid-19. Hydroxychloroquine is used in one category of therapies, while antiviral drugs used in treating HIV are included in a second method for the cure. The market for specialized antivirals and antimalarials has increased demand for both of these methods. The pharmaceutical companies must also be viewed as an indicator of the off-label for these drug groups. At present, neither of these techniques has been approved by the WHO or speculated on whether one is better than the other.

Key Players
Company Overview
Business Strategy
Key Product Offerings
Financial Performance
Key Performance Indicators
Risk Analysis
Recent Development
Regional Presence
SWOT Analysis
Coherus Biosciences
Merck & Co.
Teva Pharmaceutical Industries
STADA Arzneimittel
Other prominent players
The U.S Biosimilars Market Report also contains an analysis of:
U.S Biosimilars Market by segment:
By Product Type
Recombinant Non-Glycosylated Proteins
Human Growth Hormone
Granulocyte Colony-Stimulating Factor
Recombinant Glycosylated Proteins
Monoclonal Antibodies
Low Molecular Weight Heparin
By Application
Autoimmune Disease
Growth Hormone Deficiency
By Manufacturer
In-house Manufacturing
Contract Manufacturing
US Biosimilars Market Dynamics
US Biosimilars Market Size
Supply & Demand
Current Trends/Issues/Challenges
Competition & Companies Involved in the Market
Value Chain of the Market
Market Drivers and Restraints

Additional information


Geography Covered

Date Published




Table of Contents

1. Executive Summary
2. US Biosimilars
2.1. Product Overview
2.2. Market Definition
2.3. Segmentation
2.4. Assumptions and Acronyms
3. Research Methodology
3.1. Research Objectives
3.2. Primary Research
3.3. Secondary Research
3.4. Forecast Model
3.5. Market Size Estimation
4. Average Pricing Analysis
5. Market Dynamics
5.1. Growth Drivers
5.2. Restraints
5.3. Opportunity
5.4. Trends
6. Correlation & Regression Analysis
6.1. Correlation Matrix
6.2. Regression Matrix
7. Recent Development, Policies & Regulatory Landscape
8. Risk Analysis
8.1. Demand Risk Analysis
8.2. Supply Risk Analysis
9. US Biosimilars Industry Analysis
9.1. Porters Five Forces
9.1.1. Threat of New Entrants
9.1.2. Bargaining Power of Suppliers
9.1.3. Threat of Substitutes
9.1.4. Rivalry
9.2. PEST Analysis
9.2.1. Political
9.2.2. Economic
9.2.3. Social
9.2.4. Technological
10. US Biosimilars Market
10.1. Market Size & forecast, 2019A-2030F
10.1.1. By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
10.1.2. By Volume (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11. US Biosimilars Market: Market Segmentation
11.1. By Regions
11.1.1. US:
• By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.2. By Product type: Market Share (2020-2030F)
11.2.1. Recombinant Non-Glycosylated Proteins, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.2.2. Recombinant Glycosylated Proteins, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

11.3. By Application: Market Share (2020-2030F)
11.3.1. Chronic & Autoimmune Disorders, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.3.2. Blood Disorders, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.3.3. Oncology, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F
11.3.4. Growth Hormone, By Value (USD Million) 2019-2030F; Y-o-Y Growth (%) 2020-2030F

12. Company Profile
12.1. Pfizer
12.1.1. Company Overview
12.1.2. Company Total Revenue (Financials)
12.1.3. Market Potential
12.1.4. Global Presence
12.1.5. Key Performance Indicators
12.1.6. SWOT Analysis
12.1.7. Product Launch
12.2. Apotex/Apobiologix
12.3. Coherus Biosciences
12.4. Merck & Co.
12.5. Biogen
12.6. Amgen
12.7. Teva Pharmaceutical Industries
12.8. STADA Arzneimittel
12.9. Other prominent players
13. Consultant Recommendation
**The above given segmentations and companies could be subjected to further modification based on in-depth feasibility studies conducted for the final deliverable.